Abstract
Fecal immunochemical testing (FIT) is the leading noninvasive colorectal cancer (CRC) screening test worldwide. Many FIT-positive patients have normal colonoscopy, and current guidelines do not support upper gastrointestinal (GI) tract evaluation of these patients.1,2 Because FIT might detect proximal GI bleeding,3 we evaluated the risk of esophageal, gastric, and small bowel cancers in FIT-positive versus FIT-negative patients in a large, multiethnic US cohort.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call